ARTHUR J HIGGINS
CIK 1142083 · Director, President and CEO · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.72M
Companies
6
Total Filings
218
Lifetime Open-Market Net
-$2.96M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBH | Director | 2,900 | $94.26 | $273.4K | $540.7K | 105 | 2026-07-02 |
| ECL | Director | 26,741 | $278.49 | $7.45M | -$4.67M | 80 | 2025-04-02 |
| Assertio Holdings, Inc. (ASRT) Delisted | Director, President and CEO | 9,454 | $23.50 | $222.2K | $177.1K | 13 | 2020-12-07 |
| ECOLAB INC. (ECL.WD) Delisted | Director | 19,503 | — | — | -$806.6K | 1 | 2020-06-03 |
| Assertio Therapeutics, Inc (DEPO) Delisted | President and CEO | 126,760 | — | — | $760.8K | 5 | 2018-02-08 |
| Endo International plc (ENDP) Delisted | Director | 50,623 | $0.29 | $14.8K | $1.04M | 10 | 2016-05-12 |
Recent Filings · Page 12 of 22
218 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-03 | ECL | Grant (A) | +397 | $26.3K | EDGAR |
| 2017-10-03 | ZBH | Grant (A) | — | $0 | EDGAR |
| 2017-07-05 | ECL | Grant (A) | +386 | $26.2K | EDGAR |
| 2017-07-05 | ZBH | Grant (A) | — | $0 | EDGAR |
| 2017-06-13 | Assertio Therapeutics, Inc (DEPO) Delisted | Buy (P) | +15,000 | $148.8K | EDGAR |
| 2017-05-16 | ZBH | Grant (A) | — | $0 | EDGAR |
| 2017-05-05 | ECL | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | ECL | Grant (A) | +408 | $26.2K | EDGAR |
| 2017-04-04 | ZBH | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.